Trials / Completed
CompletedNCT04153981
A Study of Insulin Glargine (LY2963016) in Adult Participants With Type 2 Diabetes in India
A Multicenter, Open-Label, Single-Arm, Phase 4 Study to Assess the Safety of Basaglar in Subjects With Type 2 Diabetes Mellitus in India
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 304 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The reason for this study is to see if insulin glargine is safe in participants with type 2 diabetes mellitus (T2DM) in India.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Insulin Glargine | Administered SC |
Timeline
- Start date
- 2019-12-16
- Primary completion
- 2021-07-30
- Completion
- 2021-07-30
- First posted
- 2019-11-06
- Last updated
- 2024-02-15
- Results posted
- 2024-02-15
Locations
11 sites across 1 country: India
Source: ClinicalTrials.gov record NCT04153981. Inclusion in this directory is not an endorsement.